In a welcome move, Axsome Therapeutics saw its Relative Strength Rating improve from 69 to 72 on Thursday.
Can You Really Time The Stock Market?
This exclusive rating from Investor's Business Daily identifies price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the stocks that go on to make the biggest gains typically have an RS Rating of at least 80 as they begin their biggest climbs. See if Axsome Therapeutics can continue to show renewed price strength and hit that benchmark.
Axsome Therapeutics is trying to complete a cup with handle with a 130.00 entry. See if the stock can clear the breakout price in volume at least 40% higher than normal. Keep in mind that it's a later-stage consolidation, and those are riskier than earlier-stage patterns.
Axsome Therapeutics reported 0% EPS growth in its most recent report. Revenue gains came in at 72%.
Axsome Therapeutics earns the No. 162 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and argenx ADR are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
